KPTI - EU drug regulator panel recommends expanding indication for Karyopharm's Nexpovio

Karyopharm Therapeutics (NASDAQ:KPTI) on Friday said a European Union drug regulator committee had recommended extending the indication for the company's medicine Nexpovio for the treatment of patients with multiple myeloma, a type of white blood cell cancer. KPTI stock +4.6% to $5.91 in morning trade. The European Medicines Agency's Committee for Medicinal Products for Human Use (OTC:CHMP) recommended approving Nexpovio in combination with Takeda's (TAK) Velcade and widely-used steroid dexamethasone for the treatment of adults with multiple myeloma who have got one to three prior lines of therapy. In Dec. 2021, KPTI had entered into a licensing agreement with pharmaceutical company Menarini Group to commercialize Nexpovio in Europe.  The U.S. FDA had previously approved Nexpovio, branded as Xpovio in the U.S., for the same indication in Dec. 2020.

For further details see:

EU drug regulator panel recommends expanding indication for Karyopharm's Nexpovio